CATX earnings analysis
What we found in CATX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Perspective remains a pre-revenue radiopharmaceutical developer: quarterly revenue was $0 versus $209,000 of grant revenue a year earlier, and diluted EPS improved to negative $0.22 from negative $0.29 despite a higher $26.8 million net loss. The company strengthened liquidity through a $164.1 million net equity financing and ended the period with $236.9 million of cash, cash equivalents and short-term investments, supporting management’s runway into late 2027. Clinical progress toward a VMT-α-NET Phase 3 study and PSV359 enrollment are positive, but increasing R&D costs, approximately $73.2 million of first-half free cash outflow and substantial manufacturing commitments remain significant risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Runway extends into late 2027
- Cash, cash equivalents and short-term investments totaled $236.9 million at June 30, 2026, up from $144.7 million at December 31, 2025, and management expects this balance to fund planned operations into late 2027.
- VMT-α-NET progresses toward Phase 3
- VMT-α-NET advanced toward Phase 3, with 76 NET patients and one meningioma patient treated as of July 31, 2026. Clinical site activation is targeted around year-end 2026, subject to regulatory feedback and protocol finalization.
- Strong equity financing bolsters liquidity
- The company raised $164.1 million net from common stock and pre-funded warrants in the six months ended June 30, 2026, including a February offering with approximately $175.0 million of gross proceeds.
- Manufacturing investment accelerates
- Operating cash use was $52.1 million in the first six months of 2026, while property and equipment additions were $21.1 million, producing approximately $73.2 million of negative free cash flow.
- PSV359 clinical enrollment advances
- PSV359 Cohort 3 fully enrolled eight patients during the second quarter of 2026 and 17 patients had received PSV359 monotherapy across three cohorts as of July 31, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Losses and cash burn are increasing
- The net loss increased to $26.8 million in the second quarter of 2026 from $21.5 million in the prior-year quarter, while first-half operating cash use rose to $52.1 million from $41.5 million.
- R&D spending expected to rise
- Research and development expense increased to $21.5 million from $16.6 million year over year in the quarter, and management anticipates a significant increase in expenses as it advances clinical assets and expands manufacturing.
- Large manufacturing commitments
- The company is committed to approximately $53.3 million of general-contractor spending for Chicago and Los Angeles facilities, in addition to approximately €49.0 million under the Comecer equipment and services agreements.
- Take-or-pay isotope commitment
- The May 2026 DOE supply agreement includes a take-or-pay commitment to purchase approximately $9.9 million of Thorium-228 during the agreement term, creating supply-cost exposure before commercial revenue exists.
- Additional financing may dilute holders
- The company expects to require additional capital until it becomes profitable, which may never occur, and its February 2026 offering increased common shares outstanding from 74.3 million at December 31, 2025 to 114.1 million at June 30, 2026.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.22
- Segment
- Radiopharmaceutical development: $0 revenue for the three months ended June 30, 2026 versus $209,000 of grant revenue in the prior-year quarter; the company has one operating and reportable segment.
What they said about what is next.
No numeric EPS or revenue guidance was provided. Management said $236.9 million of cash, cash equivalents and short-term investments should fund current planned clinical milestones and operational investments into late 2027, while expenses are expected to increase significantly.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 11, 2026
- CATX reported Q1 2026 results with a revenue of $76 million, significantly lower than the estimated $179.74 million, reflecting a -78.8% decline from the prior quarter's revenue of $342 million. EPS came in at -$0.25, a…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CATX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever